Skip to Content


Office of the Director, National Institutes of Health; Notice of Meeting

Document Details

Information about this document as published in the Federal Register.

Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble Start Printed Page 8618

Pursuant to section 10(a) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of the Recombinant DNA Advisory Committee.

The meeting will be open to the public, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

Name of Committee: Recombinant DNA Advisory Committee.

Date: March 8-10, 2000.

Time: March 8—9:00 am to 5:00 pm; March 9—8:00 am to 5:30 pm; March 10—8:00 am to 5:00 pm.

Agenda: The meeting will be open to the public. The agenda will include a discussion with the Advisory Committee to the Director Working Group on NIH Oversight of Clinical Gene Transfer Research, review of novel human gene transfer protocols, continued deliberation about on issues involving serious adverse event reporting, and a topic raised by a member of the public (separate notice to follow). Additional information is also available at ORDA's web site:​od/​oba/​.

Place: National Institutes of Health, Building 31, Conference Room 10, Bethesda, MD 20892.

Contact Person: Amy P. Patterson, MD, Acting Executive Secretary, Office of Biotechnology Activities, National Institutes of Health, MSC 7010, 6000 Executive Boulevard, Suite 302, Bethesda, MD 20892-7010, 301-496-9838.

OMB's “Mandatory Information Requirements for Federal Assistance Program Announcements” (45 FR 39592, June 11, 1980) requires a statement concerning the official government programs contained in the Catalog of Federal Domestic Assistance. Normally NIH lists in its announcements the number and title of affected individual programs for the guidance of the public. Because the guidance in this notice covers virtually every NIH and Federal research program in which DNA recombinant molecule techniques could be used, it has been determined not to be cost effective or in the public interest to attempt to list these programs. Such a list would likely require several additional pages. In addition, NIH could not be certain that every Federal program would be included as many Federal agencies, as well as private organizations, both national and international, have elected to follow the NIH Guidelines. In lieu of the individual program listing, NIH invites readers to direct questions to the information address above about whether individual programs listed in the Catalog of Federal Domestic Assistance are affected.

Start Signature

Dated: February 11, 2000.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory Committee Policy.

End Signature End Preamble

[FR Doc. 00-4007 Filed 2-17-00; 8:45 am]